Competition from Pharmaceutical Companies and Research Institutions in Japan and Overseas
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「The pharmaceutical industry is intensely competitive, with numerous companies and research institutions in Japan and overseas, including global industry leaders, and technological innovation is advancing rapidly.」
Competition risks involving pharmaceutical companies and research institutions in Japan and overseas continue to be disclosed. - FY2020RestatedAnnual report
「The pharmaceutical industry is intensely competitive, with numerous companies and research institutions in Japan and overseas, including global industry leaders, and technological innovation is advancing rapidly.」
Competition risks involving pharmaceutical companies and research institutions in Japan and overseas continue to be disclosed. - FY2019RestatedAnnual report
「The pharmaceutical industry is intensely competitive, with numerous companies and research institutions in Japan and overseas, including global industry leaders, and technological innovation is advancing rapidly.」
Competition risks involving pharmaceutical companies and research institutions in Japan and overseas continue to be disclosed. - FY2017First statedAnnual report
「The pharmaceutical industry is intensely competitive, with numerous companies and research institutions in Japan and overseas, including global industry leaders, and technological innovation is advancing rapidly.」
The Company indicates that competition with companies and research institutions in Japan and overseas may prevent it from maintaining an advantage in research, development, manufacturing and sales.